The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome

Po Kai Yang, Chih Yuan Hsu, Mei Jou Chen, Mei Yu Lai, Zheng Rong Li, Chen Hsin Chen, Shee Uan Chen, Hong Nerng Ho

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Context: The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied. Objective: The effects of metformin on women with PCOS during 24 months with respect to menses, hormones, and metabolic profiles are assessed. Design: Prospective cohort. Setting: A reproductive endocrinology clinic in a university-affiliated medical center. Patients: One hundred nineteen women with PCOS, defined by the Rotterdam criteria, were enrolled. Intervention: Metformin was given daily for 24 months. Main Outcome Measures: The primary outcome was the proportion of patients with regular menstruation during treatment. Changes in anthropometric, hormonal, and metabolic parameters were also assessed. Analyses were performed using segmented regression analysis with a generalized estimating equation methodology. Outcomes are expressed as magnitude of change from the baseline. Results: Both overweight (OW) and normal-weight (NW) women with PCOS had increased menstrual frequency and decreased body mass index (BMI), testosterone, and luteinizing hormone levels in the first 6 months. Further stratification showed that NW women exhibiting elevated testosterone at baseline had the largest magnitude of improvement at 6 months [odds ratio (OR), 7.21; 95% confidence interval (CI), 2.35 to 22.17], whereas OW patients with normal testosterone were most likely to achieve normal menses at 12 months (OR, 0.63; 95% CI, 0.47 to 0.77). Conclusions: Metformin was associated with improvements in the menstrual cycle and most hormonal profiles in OW and NW women with PCOS during 24 months of treatment. Most parameters reached maximal response and steady-state after 6 months. Phenotypic differences in baseline BMI and testosterone level can be used as patient selection criteria or treatment prognostics.

Original languageEnglish
Pages (from-to)890-899
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number3
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Menstruation
Metabolome
Polycystic Ovary Syndrome
Metformin
Testosterone
Hormones
Endocrinology
Weights and Measures
Patient Selection
Body Mass Index
Luteinizing Hormone
Odds Ratio
Regression analysis
Confidence Intervals
Menstrual Cycle
Therapeutics
Regression Analysis
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. / Yang, Po Kai; Hsu, Chih Yuan; Chen, Mei Jou; Lai, Mei Yu; Li, Zheng Rong; Chen, Chen Hsin; Chen, Shee Uan; Ho, Hong Nerng.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 3, 01.01.2018, p. 890-899.

Research output: Contribution to journalArticle

Yang, Po Kai ; Hsu, Chih Yuan ; Chen, Mei Jou ; Lai, Mei Yu ; Li, Zheng Rong ; Chen, Chen Hsin ; Chen, Shee Uan ; Ho, Hong Nerng. / The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 3. pp. 890-899.
@article{f100b75dead5499a8fb3654bc822b412,
title = "The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome",
abstract = "Context: The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied. Objective: The effects of metformin on women with PCOS during 24 months with respect to menses, hormones, and metabolic profiles are assessed. Design: Prospective cohort. Setting: A reproductive endocrinology clinic in a university-affiliated medical center. Patients: One hundred nineteen women with PCOS, defined by the Rotterdam criteria, were enrolled. Intervention: Metformin was given daily for 24 months. Main Outcome Measures: The primary outcome was the proportion of patients with regular menstruation during treatment. Changes in anthropometric, hormonal, and metabolic parameters were also assessed. Analyses were performed using segmented regression analysis with a generalized estimating equation methodology. Outcomes are expressed as magnitude of change from the baseline. Results: Both overweight (OW) and normal-weight (NW) women with PCOS had increased menstrual frequency and decreased body mass index (BMI), testosterone, and luteinizing hormone levels in the first 6 months. Further stratification showed that NW women exhibiting elevated testosterone at baseline had the largest magnitude of improvement at 6 months [odds ratio (OR), 7.21; 95{\%} confidence interval (CI), 2.35 to 22.17], whereas OW patients with normal testosterone were most likely to achieve normal menses at 12 months (OR, 0.63; 95{\%} CI, 0.47 to 0.77). Conclusions: Metformin was associated with improvements in the menstrual cycle and most hormonal profiles in OW and NW women with PCOS during 24 months of treatment. Most parameters reached maximal response and steady-state after 6 months. Phenotypic differences in baseline BMI and testosterone level can be used as patient selection criteria or treatment prognostics.",
author = "Yang, {Po Kai} and Hsu, {Chih Yuan} and Chen, {Mei Jou} and Lai, {Mei Yu} and Li, {Zheng Rong} and Chen, {Chen Hsin} and Chen, {Shee Uan} and Ho, {Hong Nerng}",
year = "2018",
month = "1",
day = "1",
doi = "10.1210/jc.2017-01739",
language = "English",
volume = "103",
pages = "890--899",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome

AU - Yang, Po Kai

AU - Hsu, Chih Yuan

AU - Chen, Mei Jou

AU - Lai, Mei Yu

AU - Li, Zheng Rong

AU - Chen, Chen Hsin

AU - Chen, Shee Uan

AU - Ho, Hong Nerng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Context: The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied. Objective: The effects of metformin on women with PCOS during 24 months with respect to menses, hormones, and metabolic profiles are assessed. Design: Prospective cohort. Setting: A reproductive endocrinology clinic in a university-affiliated medical center. Patients: One hundred nineteen women with PCOS, defined by the Rotterdam criteria, were enrolled. Intervention: Metformin was given daily for 24 months. Main Outcome Measures: The primary outcome was the proportion of patients with regular menstruation during treatment. Changes in anthropometric, hormonal, and metabolic parameters were also assessed. Analyses were performed using segmented regression analysis with a generalized estimating equation methodology. Outcomes are expressed as magnitude of change from the baseline. Results: Both overweight (OW) and normal-weight (NW) women with PCOS had increased menstrual frequency and decreased body mass index (BMI), testosterone, and luteinizing hormone levels in the first 6 months. Further stratification showed that NW women exhibiting elevated testosterone at baseline had the largest magnitude of improvement at 6 months [odds ratio (OR), 7.21; 95% confidence interval (CI), 2.35 to 22.17], whereas OW patients with normal testosterone were most likely to achieve normal menses at 12 months (OR, 0.63; 95% CI, 0.47 to 0.77). Conclusions: Metformin was associated with improvements in the menstrual cycle and most hormonal profiles in OW and NW women with PCOS during 24 months of treatment. Most parameters reached maximal response and steady-state after 6 months. Phenotypic differences in baseline BMI and testosterone level can be used as patient selection criteria or treatment prognostics.

AB - Context: The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied. Objective: The effects of metformin on women with PCOS during 24 months with respect to menses, hormones, and metabolic profiles are assessed. Design: Prospective cohort. Setting: A reproductive endocrinology clinic in a university-affiliated medical center. Patients: One hundred nineteen women with PCOS, defined by the Rotterdam criteria, were enrolled. Intervention: Metformin was given daily for 24 months. Main Outcome Measures: The primary outcome was the proportion of patients with regular menstruation during treatment. Changes in anthropometric, hormonal, and metabolic parameters were also assessed. Analyses were performed using segmented regression analysis with a generalized estimating equation methodology. Outcomes are expressed as magnitude of change from the baseline. Results: Both overweight (OW) and normal-weight (NW) women with PCOS had increased menstrual frequency and decreased body mass index (BMI), testosterone, and luteinizing hormone levels in the first 6 months. Further stratification showed that NW women exhibiting elevated testosterone at baseline had the largest magnitude of improvement at 6 months [odds ratio (OR), 7.21; 95% confidence interval (CI), 2.35 to 22.17], whereas OW patients with normal testosterone were most likely to achieve normal menses at 12 months (OR, 0.63; 95% CI, 0.47 to 0.77). Conclusions: Metformin was associated with improvements in the menstrual cycle and most hormonal profiles in OW and NW women with PCOS during 24 months of treatment. Most parameters reached maximal response and steady-state after 6 months. Phenotypic differences in baseline BMI and testosterone level can be used as patient selection criteria or treatment prognostics.

UR - http://www.scopus.com/inward/record.url?scp=85047898692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047898692&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-01739

DO - 10.1210/jc.2017-01739

M3 - Article

VL - 103

SP - 890

EP - 899

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -